Faster, Please! • 1645 implied HN points • 18 Feb 26
- The FDA reversed its halt and will review Moderna's mRNA flu vaccine. The episode shows political backlash can inject major regulatory uncertainty into vaccine approvals.
- Rising vaccine skepticism is chilling the mRNA field—venture funding, manufacturing plans, and federal contracts have been cut or canceled. This threatens not just flu shots but future work on cancer vaccines, autoimmune treatments, and pandemic preparedness.
- Without clearer funding and oversight, the U.S. vaccine enterprise risks being dismantled and important medical advances may be foreclosed. Congress may need to direct funds and set enforceable milestones to preserve vaccine R&D.